129 related articles for article (PubMed ID: 9209317)
1. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
[TBL] [Abstract][Full Text] [Related]
2. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
[TBL] [Abstract][Full Text] [Related]
3. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
5. [Current status of HIV protease inhibitors].
Yang QG; He XC; Bai DL
Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
[No Abstract] [Full Text] [Related]
6. Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy.
von der Helm K
Biol Chem; 1996 Dec; 377(12):765-74. PubMed ID: 8997487
[TBL] [Abstract][Full Text] [Related]
7. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
8. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
Wei Y; Ma CM; Hattori M
Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
[TBL] [Abstract][Full Text] [Related]
10. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
11. Adaptive inhibitors of the HIV-1 protease.
Ohtaka H; Freire E
Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
13. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
14. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
15. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
16. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
17. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state].
Kiso Y
Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066
[No Abstract] [Full Text] [Related]
18. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
20. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Dunn BM; Pennington MW; Frase DC; Nash K
Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]